VRAYLAR (cariprazine HCl)
ANTIPSYCHOTICS·SCHIZOPHRENIA·+4
Allergan
Indication
Major depressive disorder treatment adjunct
Major depressive disorder treatment adjunct refers to the use of an add-on therapeutic agent alongside an established antidepressant regimen in patients who have experienced an incomplete or inadequate clinical response to standard monotherapy. Read more about Major depressive disorder treatment adjunct
117 drugs 73 manufacturers
Drugs that treat it
Common Major depressive disorder treatment adjunct therapies.
OLANZAPINE ODT (olanzapine)
SCHIZOPHRENIA·+3
PAR HEALTH USA,
OLANZAPINE ODT (olanzapine)
ANTIPSYCHOTICS·SCHIZOPHRENIA·+3
TORRENT PHARMAC
OLANZAPINE ODT (olanzapine)
ANTIPSYCHOTICS·SCHIZOPHRENIA·+3
DR.REDDY'S LAB
OLANZAPINE ODT (olanzapine)
ANTIPSYCHOTICS·SCHIZOPHRENIA·+3
SUN PHARMACEUTI
OLANZAPINE ODT (olanzapine)
ANTIPSYCHOTICS·SCHIZOPHRENIA·+3
TEVA USA
OLANZAPINE ODT (olanzapine)
ANTIPSYCHOTICS·SCHIZOPHRENIA·+3
APOTEX CORP
OLANZAPINE
ANTIPSYCHOTICS·SCHIZOPHRENIA·+3
TORRENT PHARMAC
OLANZAPINE
ANTIPSYCHOTICS·SCHIZOPHRENIA·+3
DR.REDDY'S LAB
Filter & compare in the drug finder →Opens the drug finder with Major depressive disorder treatment adjunct preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMajor depressive disorder treatment adjunct refers to the use of an add-on therapeutic agent alongside an established antidepressant regimen in patients who have experienced an incomplete or inadequate clinical response to standard monotherapy.
Major depressive disorder is a prevalent, debilitating psychiatric condition affecting the central nervous system, characterized by persistent depressed mood, anhedonia, neurovegetative disturbances, and cognitive dysfunction.
Pathophysiologically, the disorder involves complex dysregulation of central monoaminergic neurotransmission, altered neuroplasticity, disrupted frontolimbic neural circuitry, and neuroendocrine dysfunction.
In this clinical state, adjunctive intervention targets residual depressive symptoms and functional impairment to help achieve clinical response or remission when primary antidepressant monotherapy proves insufficient.
- fda.gov
Major depressive disorder treatment adjunct refers to the use of an add-on therapeutic agent alongside an established antidepressant regimen in patients who have experienced an incomplete or inadequate clinical response to standard monotherapy
- ajmc.com
Major depressive disorder treatment adjunct refers to the use of an add-on therapeutic agent alongside an established antidepressant regimen in patients who have experienced an incomplete or inadequate clinical response to standard monotherapy In this clinical state, adjunctive intervention targets residual depressive symptoms and functional impairment to help achieve clinical response or remission when primary antidepressant monotherapy proves insufficient
- jnj.com
Major depressive disorder is a prevalent, debilitating psychiatric condition affecting the central nervous system, characterized by persistent depressed mood, anhedonia, neurovegetative disturbances, and cognitive dysfunction In this clinical state, adjunctive intervention targets residual depressive symptoms and functional impairment to help achieve clinical response or remission when primary antidepressant monotherapy proves insufficient
- nih.gov
Major depressive disorder is a prevalent, debilitating psychiatric condition affecting the central nervous system, characterized by persistent depressed mood, anhedonia, neurovegetative disturbances, and cognitive dysfunction
- nih.gov
Major depressive disorder is a prevalent, debilitating psychiatric condition affecting the central nervous system, characterized by persistent depressed mood, anhedonia, neurovegetative disturbances, and cognitive dysfunction
- nih.gov
Pathophysiologically, the disorder involves complex dysregulation of central monoaminergic neurotransmission, altered neuroplasticity, disrupted frontolimbic neural circuitry, and neuroendocrine dysfunction
- nih.gov
Pathophysiologically, the disorder involves complex dysregulation of central monoaminergic neurotransmission, altered neuroplasticity, disrupted frontolimbic neural circuitry, and neuroendocrine dysfunction
Personalize your experience
Follow Major depressive disorder treatment adjunct and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.